Clicky

Autolus Therapeutics plc(AUTL)

Description: Autolus Therapeutics Ltd is a biopharmaceutical company. It is engaged in the development of next-generation programmed T cell therapies for the treatment of cancer. The company's pipeline includes AUTO1, AUTO2, AUTO3, AUTO4, and AUTO6.


Keywords: Biotechnology Cancer Biopharmaceutical Life Sciences Pharmacy Treatment Of Cancer

Home Page: www.autolus.com

AUTL Technical Analysis

The MediaWorks
London, W12 7FP
United Kingdom
Phone: 44 20 3829 6230


Officers

Name Title
Dr. Christian Martin Itin Ph.D. CEO & Director
Dr. Martin Pule M.D., MBBS Founder, Sr. VP & Chief Scientific Officer
Mr. Christopher Vann Sr. VP & COO
Mr. David Brochu Sr. VP & Chief Technical Officer
Mr. Andrew J. Oakley ACA, BEcon, MBA Sr. Advisor
Mr. Brent Rice Sr. VP, Chief Commercial Officer & Site Head of US
Dr. Edgar E. W. Braendle M.D., Ph.D. Sr. VP & Chief Devel. Officer
Dr. Lucinda Crabtree Ph.D. Chief Financial Officer
Ms. Olivia Manser Director of Investor Relations
Dr. Chris Williams Sr. VP of Corp. Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.0462
Price-to-Sales TTM: 62.0976
IPO Date: 2018-06-22
Fiscal Year End: September
Full Time Employees: 324
Back to stocks